Adial Pharmaceuticals (ADIL) News Today $0.46 +0.02 (+4.36%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.38 -0.07 (-16.28%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADIL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Adial Pharmaceuticals (NASDAQ:ADIL) Stock Rating Upgraded by Wall Street ZenJuly 28, 2025 | americanbankingnews.comAdial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing RequirementJuly 16, 2025 | finance.yahoo.comAdial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing RequirementJuly 16, 2025 | globenewswire.comAdial Pharmaceuticals Files PCT Patent Application to Protect Core ...July 11, 2025 | morningstar.comMAdial Pharmaceuticals Files Update to Provisional Patent ... - NasdaqJuly 11, 2025 | nasdaq.comAdial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045July 9, 2025 | globenewswire.comADIL - Adial Pharmaceuticals Inc News - MorningstarJuly 2, 2025 | morningstar.comMAdial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product SupplyJune 25, 2025 | globenewswire.comAdial Pharmaceuticals, Inc. (ADIL) Stock Price, Quote, News & Analysis | Seeking AlphaJune 24, 2025 | seekingalpha.comAdial Pharmaceuticals prices $3.6 million public offeringJune 18, 2025 | investing.comAdial Pharmaceuticals Announces Pricing of $3.6 Million Public OfferingJune 17, 2025 | finance.yahoo.comAdial Pharmaceuticals Advances Toward Phase 3 Development for AD04June 11, 2025 | finance.yahoo.comAdial Pharmaceuticals Reports First Quarter 2025 Business Update and Financial ResultsMay 17, 2025 | nasdaq.comAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | finanznachrichten.deAdial Pharmaceuticals Receives Development Milestone Payment from Adovate Following Phase 1 Clinical Trial Initiation for Asthma TreatmentMay 15, 2025 | nasdaq.comAdial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | globenewswire.comAdial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 StudyMay 13, 2025 | globenewswire.comAdial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug AdministrationMay 9, 2025 | finance.yahoo.comAdial Pharmaceuticals raises $2.75MMay 7, 2025 | bizjournals.comAdial Pharmaceuticals raises $2.75MMay 7, 2025 | bizjournals.comAdial Pharmaceuticals Secures Patent for Novel Treatment of Alcohol and Opioid Disorders Using AD04 in Genetically Identified PatientsMay 3, 2025 | nasdaq.comAdial Pharmaceuticals secures patent for addiction treatmentMay 2, 2025 | investing.com1ADIL : EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent...May 2, 2025 | benzinga.comAdial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross ProceedsMay 2, 2025 | globenewswire.comAdial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use DisordersMay 1, 2025 | globenewswire.comAdial Pharmaceuticals appoints new COO Tony GoodmanMarch 23, 2025 | uk.investing.comAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business UpdateMarch 4, 2025 | finanznachrichten.deAdial Pharmaceuticals expects cash to fund operations into 2H of 2025March 4, 2025 | markets.businessinsider.comAdial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business UpdateMarch 4, 2025 | globenewswire.comAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04February 26, 2025 | finanznachrichten.deAdial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04February 25, 2025 | markets.businessinsider.comAdial says FDA feedback confirms proposed strategy to AD04 Phase 3 formulationFebruary 25, 2025 | markets.businessinsider.comAdial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04February 25, 2025 | globenewswire.comAdial awarded patent covering genetic approach to alcoholism by USPTOFebruary 19, 2025 | markets.businessinsider.comAdial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug DependenciesFebruary 19, 2025 | globenewswire.comAdial Pharmaceuticals awarded new U.S. patent on genotype-specific treatmentFebruary 12, 2025 | markets.businessinsider.comEXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related DisordersFebruary 12, 2025 | finance.yahoo.comAdial Pharmaceuticals secures new patent for addiction treatmentFebruary 12, 2025 | msn.comAdial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related DisordersFebruary 12, 2025 | globenewswire.comAdial Pharmaceuticals Completes Pharmacokinetics Study of AD04, Prepares for FDA End-of-Phase 2 InteractionJanuary 31, 2025 | nasdaq.comAdial completes key study for alcohol disorder drugJanuary 29, 2025 | msn.comAdial Pharmaceutical Announces Positive Findings From AD04-103 Pharmacokinetics StudyJanuary 29, 2025 | markets.businessinsider.comAdial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use DisorderJanuary 29, 2025 | globenewswire.comAdial Pharma stock hits 52-week low at $0.72 amid market challengesJanuary 28, 2025 | msn.comAdial Pharmaceuticals files to sell 5.0M shares of common stock for holdersDecember 20, 2024 | markets.businessinsider.comAdial granted U.S. patent for treatment of alcohol, drug dependenceDecember 3, 2024 | markets.businessinsider.comEXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype CombinationsDecember 3, 2024 | finance.yahoo.comAdial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype CombinationsDecember 3, 2024 | globenewswire.comAdial Pharmaceuticals Advances AD04 with Promising Study ResultsNovember 19, 2024 | markets.businessinsider.comMaxim Group Sticks to Their Hold Rating for Adial Pharmaceuticals (ADIL)November 16, 2024 | markets.businessinsider.com Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Email Address ADIL Media Mentions By Week ADIL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADIL News Sentiment▼0.000.63▲Average Medical News Sentiment ADIL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADIL Articles This Week▼11▲ADIL Articles Average Week Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FibroBiologics News Tenax Therapeutics News Longeveron News Cyclacel Pharmaceuticals News Aytu BioPharma News Reviva Pharmaceuticals News Cadrenal Therapeutics News Lisata Therapeutics News Dare Bioscience News Natural Alternatives International News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADIL) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.